Global Hemophilia Markets, 2020-2026: Focus on Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates and Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Hemophilia Market 2020-2026" report has been added to ResearchAndMarkets.com's offering.

Global Hemophilia Market Size, Share & Trends Analysis Report By Type (Hemophilia A, Hemophilia B, and, Others), By Therapy (Replacement Therapy, Gene Therapy, and Others), By Product Type (Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates and Others) Forecast Period (2020-2026).

The global hemophilia market is anticipated to grow at a CAGR of 6% during the forecast period. Hemophilia is a disease associated with the genetic inheritance in which patients are not able to produce sufficient amounts of the blood clotting proteins. Hence, in cases of injury, the clotting of blood is very slow in patients as a result patients often suffer spontaneous, painful bleeding into muscle tissue and joints. The increasing awareness regarding the condition and increasing disposable income of people across the globe is driving the hemophilia market growth.

The global hemophilia market is segmented based on type, therapy, and product type. Based on the type, the market is sub-segmented into hemophilia A, hemophilia B, and others. Based on the therapy, the market is sub-segmented into replacement therapy, gene therapy, and others. Further, based on the product type, the market is subdivided into recombinant coagulation factor concentrates, plasma-derived coagulation, and other factor concentrates.

The global hemophilia market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to show significant growth with a considerable market share during the forecast period. The growth in the region is owing to the high diagnosis rate and the ability to spend a high amount on the treatment.

The key players of the global hemophilia market include Baxter International, Inc., BioMarin Pharmaceutical Inc., CSL Ltd., F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including merger & acquisition, collaborations with government, funding, new drug launches, and various other advancements to stay competitive in the market. For instance, in April 2019, Novo Nordisk A/S invested approximately100 million in its production site in Kalundborg, Denmark, for the upgrading and expansion of the facilities to ramp up its hemophilia drug production.

Key Topics Covered:

1. Report Summary

1.1. Research Business Functions and Tools

1.2. Market Breakdown

2. Market Overview and Insights

2.1. Scope of the Report

2.2. Analyst Insight & Current Market Trends

2.3. Rules & Regulations

3. Competitive Landscape

3.1. Company Share Analysis

3.2. Key Strategy Analysis

3.3. Key Company Analysis

3.3.1. Baxter International, Inc.

3.3.2. Bayer AG

3.3.3. CSL Ltd.

3.3.4. F. Hoffmann-La Roche Ltd.

3.3.5. Novo Nordisk A/S

4. Market Determinants

4.1 Motivators

4.2 Restraints

4.1. Opportunities

5. Market Segmentation

5.1. Global Hemophilia Market by Type

5.1.1. Hemophilia A

5.1.2. Hemophilia B

5.1.3. Others (Hemophilia C)

5.2. Global Hemophilia Market by Therapy

5.2.1. Replacement Therapy

5.2.2. Gene Therapy

5.2.3. Others

5.3. Global Hemophilia Market by Product Type

5.3.1. Recombinant Coagulation Factor Concentrates

5.3.2. Plasma-derived Coagulation Factor Concentrates

5.3.3. Other

6. Regional Analysis

7. Company Profiles

7.1. Alnylam Pharmaceuticals, Inc

7.2. Baxter International, Inc.

7.3. Bayer AG

7.4. BioMarin Pharmaceutical Inc.

7.5. Biotest AG

7.6. Catalyst Biosciences Inc.

7.7. CSL Ltd.

7.8. Emergent BioSolutions Inc.

7.9. F. Hoffmann-La Roche Ltd.

7.10. GC Pharma (Green Cross Corp.)

7.11. Genentech Inc. (HEMLIBRA)

7.12. Grifols, S.A.

7.13. Kedrion S.p.A

7.14. Medexus Pharmaceuticals, Inc.

7.15. Nektar Therapeutics

7.16. Novo Nordisk A/S

7.17. Octapharma AG

7.18. Pfizer, Inc.

7.19. Sanofi SA

7.20. Spark Therapeutics, Inc.

7.21. Swedish Orphan Biovitrum AB

7.22. Takeda Pharmaceutical Company Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/uqbzc7